Home / Pharmaceuticals / Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Jan 2019 | Report Code: 59521-01-19

The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2018 to 2026. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted. Cervical cancer can be prevented by performing early screening test and vaccination using Gardasil against HPV infection.

It is quite obvious that generic market is having the major economic share in the cervical cancer treatment market, however the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in the phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.

Market Synopsis

Cervical Cancer Treatment Market

Affordable reimbursement scenario drive the chemotherapy market growth

Currently, chemotherapy is reigning the product segment for cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy such as external beam therapy and brachytherapy are given concurrently with chemotherapy in some stages of cervical cancer to give excellent synergistic effect. The side effects associated with both the therapy are severe thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab) etc. are used in cancer immunotherapy which possesses impressive clinical efficacy, dose tolerance and patient compliance. Targeted drug therapy will be the fastest growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials such as nimotuzumab and Atezolizumab. Cervical hysterectomy involves the removal of uterus, cervix and sometimes the fallopian tubes in women suffering with early stage cervical cancer.

Cervical Cancer Treatment Market
 

Increasing number of patients screened for cervical cancer drive the market growth in North America

North America is the clear leader for the geographical segment in the cervical cancer treatment market. As per the latest research findings of American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed for cervical cancer and around 4,250 women will die from cervical cancer. Rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drives the market growth in North America. According to the facts presented by World Health Organization (WHO) it is estimated that in 25,000 women for the European region will die from cervical cancer. Existence of major players such as Merck & Co., Inc., F.Hoffman La-Roche AG, GlaxoSmithkline Plc., etc. propel the cervical cancer market growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to the proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and presence of huge generic market.

Cervical Cancer Treatment Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Cervical Cancer Treatment Market 

Report Scope by Segments

The market is subsegmented by product and geographical segment.

By Product (2016–2026; US$ Mn)

  • Chemotherapy
  • Targeted Therapy
  • Surgical Procedure
  • Radiation Therapy
  • Others
    • Pipeline Analysis
      • Phase III Drugs
      • Z-100
      • ADXS11-001
      • Nimotuzumab
      • Atezolizumab
    • Tabular Representation of Drug Pipeline in Phase II and I

Geography Segment (2016–2026; US$ Mn)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of MEA

Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc. 

Key questions answered in this report

  • What are latest market trends prevailing in the cervical cancer treatment market?
  • Which biopharmaceutical companies are competing in the cervical cancer treatment market?
  • What are the clinical manifestations occurring in the cervical cancer?
  • What are the screening test performed and treatment regimen adopted for the treatment of cervical cancer?
  • What led to the rise of targeted therapy and how will it be performing during the forecast period from 2018 to 2026?
  • What are the major attributes responsible for the dominance of North America in the cervical cancer treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Cervical Cancer Treatment Market Portraiture
2.2. Global Cervical Cancer Treatment Market, by Product, 2017 (US$ Mn)
2.3. Global Cervical Cancer Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Cervical Cancer Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Cervical Cancer Treatment Market, by Key Players, 2017

Chapter 4. Global Cervical Cancer Treatment Market, by Product
4.1. Overview
4.2. Chemotherapy
4.3. Targeted Therapy
4.4. Surgical Procedure
4.5. Radiation Therapy
4.6. Others
4.7. Pipeline Analysis
4.7.1. Phase III Drugs
4.7.1.1. Z-100
4.7.1.2. ADXS11-001
4.7.1.3. Nimotuzumab
4.7.1.4. Atezolizumab
4.7.2. Tabular Representation of Drug Pipeline in Phase II and I

Chapter 5. Global Cervical Cancer Treatment Market, by Geography
5.1. Overview
5.2. North America Cervical Cancer Treatment Market Analysis, 2016 – 2026
5.2.1. North America Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
5.2.2. North America Cervical Cancer Treatment Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Cervical Cancer Treatment Market Analysis, 2016 – 2026
5.3.1. Europe Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
5.3.2. Europe Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Cervical Cancer Treatment Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Cervical Cancer Treatment Market Analysis, 2016 – 2026
5.5.1. Latin America Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa Cervical Cancer Treatment Market Analysis, 2016 – 2026
5.6.1. MEA Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
5.6.2. MEA Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Biocon Ltd.
6.3. CooperSurgical, Inc.
6.4. Eli Lilly & Company
6.5. F.Hoffman La-Roche AG
6.6. GlaxoSmithKline, Plc.
6.7. Ethicon, Inc.
6.8. Merck & Co., Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Varian Medical Systems, Inc.

FIG. 1 Cervical Cancer Treatment Market: Research Methodology
FIG. 2 Cervical Cancer Treatment: Market Segmentation
FIG. 3 Global Cervical Cancer Treatment Market, by Product, 2017 (US$ Mn)
FIG. 4 Global Cervical Cancer Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global Cervical Cancer Treatment Market, by Key Players, 2017
FIG. 7 Global Chemotherapy Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Targeted Therapy Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 Global Surgical Procedure Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 10 Global Radiation Therapy Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 11 Global Other Products Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 17 China Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 18 Japan Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of MEA Cervical Cancer Treatment Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Cervical Cancer Treatment Market Portraiture
TABLE 2 Global Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 Global Cervical Cancer Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 5 North America Cervical Cancer Treatment Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 Europe Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 7 Europe Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Latin America Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Middle East and Africa Cervical Cancer Treatment Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East and Africa Cervical Cancer Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Biocon Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 CooperSurgical, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 F.Hoffman La-Roche AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Ethicon, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients